Annual report
9158.TEDINET S100TWCD
Period2023-04-01 → 2024-03-31
Filed2024-06-27
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 132
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥33.0bn | 2023-04-01 → 2024-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥35.2bn | 2022-04-01 → 2023-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥35.3bn | 2021-04-01 → 2022-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥16.6bn | 2020-04-01 → 2021-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥3.7bn | 2023-04-01 → 2024-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥3.7bn | 2022-04-01 → 2023-03-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥4.1bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥3.6bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥3.6bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥1.6bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | ¥2.6bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥2.4bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥2.7bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥1.1bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | ¥2.6bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss IFRS |
| Net income | ¥2.4bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss IFRS |
| Total assets | ¥62.8bn | at 2024-03-31 | Cons. | Assets IFRS |
| Total assets | ¥39.8bn | at 2023-03-31 | Cons. | Assets IFRS |
| Total assets | ¥34.5bn | at 2022-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥28.4bn | at 2021-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥34.8bn | at 2024-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥27.8bn | at 2023-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥28.0bn | at 2024-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥11.9bn | at 2023-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥9.7bn | at 2022-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥27.3bn | at 2024-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥11.7bn | at 2023-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥9.5bn | at 2022-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥4.7bn | at 2021-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥8.3bn | at 2024-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥4.1bn | at 2023-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥4.4bn | at 2022-03-31d | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥3.6bn | at 2021-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥4.2bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥2.4bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥6.6bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥2.1bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | −¥14.7bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥6.7bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥1.5bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥2.4bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | ¥14.4bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥4.0bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥4.4bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥591m | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥93.99 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥113.9 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥129.68 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥52.71 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥93.99 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥113.9 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥129.68 | 2021-04-01 → 2022-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥52.71 | 2020-04-01 → 2021-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥931.79 | at 2024-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥533.1 | at 2023-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥453.12 | at 2022-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥226.83 | at 2021-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 43.5% | at 2024-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 29.4% | at 2023-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 27.4% | at 2022-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 16.6% | at 2021-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | 13.3% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 22.9% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 38.1% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 27.1% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 3,743 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 2,994 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 2,470 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 1,819 | at 2021-03-31d | Cons. | Number of employees |
| Revenue | ¥7.8bn | 2023-04-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥14.3bn | 2022-04-01 → 2023-03-31 | Standalone | Net sales |
| Revenue | ¥15.4bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥4.0bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥3.8bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥2.2bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Operating income | ¥1.9bn | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Ordinary income | ¥1.9bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥1.8bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥2.4bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥795m | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥312m | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥1.9bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥1.8bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Net income | ¥1.3bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥1.3bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥1.7bn | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥574m | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥122m | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥45.5bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥28.4bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥23.9bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥19.4bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥18.6bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥23.2bn | at 2024-03-31 | Standalone | Liabilities |
| Total liabilities | ¥20.3bn | at 2023-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥22.3bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥8.1bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥7.4bn | at 2022-03-31d | Standalone | Net assets |
| Net assets / equity | ¥3.9bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥3.3bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥3.4bn | at 2024-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥554m | at 2023-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥46.01 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥60.21 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥78.53 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥25.98 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥1,145.5 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥759.3 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥365.69 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥335.57 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥176.49 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥30,101.95 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 48.8% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 28.4% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 30.9% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 20.1% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 17.9% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 8.4% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 16.6% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 30.6% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 15.9% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 5.4% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 29,990,400 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 113,152 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 104,352 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 104,352 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 104,352 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 434 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 423 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 374 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 304 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 310 | at 2020-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 55
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2024-03-31 | 5 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2024-03-31 | ¥205m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2024-03-31 | ¥205m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2024-03-31 | ¥18m |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2024-03-31 | −¥696m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2024-03-31 | −¥696m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥1.2bn |
| Hospicereportable segment | employees | at 2024-03-31 | 1391 pure |
| Hospicereportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥10.4bn |
| Hospicereportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥10.4bn |
| Hospicereportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥1m |
| Hospicereportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥349m |
| In Home Nursingreportable segment | employees | at 2024-03-31 | 1455 pure |
| In Home Nursingreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥10.9bn |
| In Home Nursingreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥10.9bn |
| In Home Nursingreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥0 |
| In Home Nursingreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥616m |
| Medical Institutionreportable segment | employees | at 2024-03-31 | 808 pure |
| Medical Institutionreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥12.2bn |
| Medical Institutionreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥11.5bn |
| Medical Institutionreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥695m |
| Medical Institutionreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥3.9bn |
| —segment total | revenue | 2023-04-01 → 2024-03-31 | ¥33.5bn |
| —segment total | revenue external | 2023-04-01 → 2024-03-31 | ¥32.8bn |
| —segment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥696m |
| —segment total | segment profit | 2023-04-01 → 2024-03-31 | ¥4.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2024-03-31 | ¥33.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2024-03-31 | ¥33.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥696m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2024-03-31 | ¥4.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2023-03-31 | ¥205m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2023-03-31 | ¥205m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2023-03-31 | ¥29m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2023-03-31 | −¥263m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2023-03-31 | −¥263m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | −¥843m |
| Hospicereportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥6.6bn |
| Hospicereportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥6.6bn |
| Hospicereportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥191m |
| In Home Nursingreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥12.2bn |
| In Home Nursingreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥12.2bn |
| In Home Nursingreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥1.4bn |
| Medical Institutionreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥16.4bn |
| Medical Institutionreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥16.2bn |
| Medical Institutionreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥263m |
| Medical Institutionreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥3.0bn |
| —segment total | revenue | 2022-04-01 → 2023-03-31 | ¥35.3bn |
| —segment total | revenue external | 2022-04-01 → 2023-03-31 | ¥35.0bn |
| —segment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥263m |
| —segment total | segment profit | 2022-04-01 → 2023-03-31 | ¥4.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2023-03-31 | ¥35.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2023-03-31 | ¥35.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥263m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2023-03-31 | ¥4.5bn |
| Medical Institutionreportable segment | employees | at 2024-03-31 | 350 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,678
| Item | Context | Value | Unit |
|---|---|---|---|
| Fiscal year cover page | FilingDateInstant | Original text (Japanese)第10期（自 2023年４月１日 至 2024年３月31日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)株式会社シーユーシー | |
| Company name in english cover page | FilingDateInstant | CUC Inc. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役 濵口 慶太 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都港区芝浦三丁目１番１号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)03（5005）0808（代表） | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)執行役員 橋本 淳 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都港区芝浦三丁目１番１号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | Original text (Japanese)03（5005）0808（代表） | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)執行役員 橋本 淳 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E37214 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 91580 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)株式会社シーユーシー | |
| Filer name in english | FilingDateInstant | CUC Inc. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第三号様式 | |
| Accounting standards | FilingDateInstant | IFRS | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Current fiscal year start date | FilingDateInstant | 2023-04-01 | |
| Current period end date | FilingDateInstant | 2024-03-31 | |
| Type of current period | FilingDateInstant | FY | |
| Current fiscal year end date | FilingDateInstant | 2024-03-31 | |
| Previous fiscal year start date | FilingDateInstant | 2022-04-01 | |
| Comparative period end date | FilingDateInstant | 2023-03-31 | |
| Previous fiscal year end date | FilingDateInstant | 2023-03-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Business results of reporting company (text) | FilingDateInstant | Text · Plus | |
| Company history (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Overview of affiliated entities (text) | FilingDateInstant | Text · Plus | |
| Information about employees (text) | FilingDateInstant | Text · Plus | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | Original text (Japanese)株式会社シーユーシー・ホスピス | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row2Member | Original text (Japanese)ソフィアメディ株式会社 | |
| Business policy business environment issues to address etc (text) | FilingDateInstant | Text · Plus | |
| Disclosure of sustainability related financial information (text) | FilingDateInstant | Text · Plus | |
| Governance (text) | FilingDateInstant | Text · Plus | |
| Strategy (text) | FilingDateInstant | Text · Plus | |
| Risk management (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 21 of 21 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |